Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Categories
https://finance.yahoo.com/news/innovent-announces-sintilimab-combination-chemotherapy-000000408.html